11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $110M | -$153M | 88.7% | -113.7% | -$163M | $125M | $111M |
| 2024 | $90M | -$127M | 90.2% | -107.1% | -$97M | $122M | $172M |
| 2023 | $83M | -$102M | 88.7% | -79.2% | -$77M | $99M | $95M |
| 2022 | $64M | -$110M | 88.1% | -122.8% | -$88M | $98M | $55M |
| 2021 | $48M | -$111M | 89.3% | -192.1% | -$86M | $0 | $44M |
| 2020 | $12M | -$128M | 91.4% | -1074.2% | -$107M | — | $53M |
| 2019 | $18000 | -$105M | 100.0% | -608211.1% | -$71M | — | $50M |
| 2018 | $1M | -$76M | -59.8% | -6842.2% | -$38M | — | $101M |
| 2017 | $8M | -$20M | 92.6% | -244.5% | -$10M | — | $37M |
| 2016 | — | -$2M | — | — | $3M | — | $21M |
| 2015 | — | -$13M | — | — | -$7M | — | $18M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $51M | -$24M | 91.9% | -39.8% | -$45M | $200M | $110M |
| Dec '25 | $38M | -$26M | 91.3% | -50.5% | -$38M | $125M | $111M |
| Sep '25 | $27M | -$33M | 88.1% | -99.7% | -$42M | $122M | $90M |
| Jun '25 | $24M | -$50M | 85.3% | -171.2% | -$40M | $123M | $93M |
| Mar '25 | $20M | -$44M | 88.5% | -182.3% | -$42M | $122M | $104M |
| Dec '24 | $25M | -$38M | 89.9% | -112.6% | -$14M | $122M | $172M |
| Sep '24 | $25M | -$24M | 90.3% | -69.6% | -$28M | $122M | $125M |
| Jun '24 | $22M | -$33M | 89.8% | -118.3% | -$24M | $98M | $220M |
| Mar '24 | $19M | -$32M | 90.8% | -137.1% | -$32M | $98M | $131M |
| Dec '23 | $24M | -$26M | 90.3% | -62.1% | -$13M | $99M | $95M |
| Sep '23 | $21M | -$22M | 88.6% | -64.7% | -$17M | $99M | $119M |
| Jun '23 | $21M | -$24M | 88.4% | -72.8% | -$20M | $98M | $20M |
| Mar '23 | $17M | -$30M | 86.8% | -128.2% | -$26M | $98M | $37M |
| Dec '22 | $18M | -$29M | 87.5% | -112.1% | -$22M | $98M | $55M |
| Sep '22 | $16M | -$26M | 87.5% | -112.4% | -$18M | $72M | $29M |
| Jun '22 | $17M | -$27M | 88.9% | -112.7% | -$24M | $71M | $81M |
| Mar '22 | $14M | -$28M | 88.8% | -161.9% | -$24M | $71M | $105M |
| Dec '21 | $16M | -$28M | 90.2% | -123.1% | -$20M | $0 | $44M |
| Sep '21 | $11M | -$30M | 89.0% | -206.5% | -$19M | — | $55M |
| Jun '21 | $13M | -$26M | 89.1% | -175.1% | -$19M | — | $63M |
How the market has priced URGN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Urogen Pharma Ltd.'s revenue has grown 56.2% per year. These are computed facts, not advice.
As of FY2025, Urogen Pharma Ltd. reported $125M of total debt against $111M of cash.
In FY2025, gross margin was 88.7%, operating margin -113.7%, and net margin -139.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.